BrainStorm Expands Manufacturing Of NurOwn For Phase 2 Progressive MS Trial

(RTTNews) - BrainStorm Cell Therapeutics Inc. (BCLI) said that it has expanded its autologous cell manufacturing capacity to produce NurOwn to support clinical trials in additional indications, including a Phase 2 progressive Multiple Sclerosis study, to begin in first quarter of 2019.

MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide. Approximately half of affected individuals will eventually develop a progressive disease, which may lead to increasing levels of motor, visual, and cognitive functional impairment and disability.

BrainStorm noted that it expanded the existing manufacturing contract with the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) at Dana-Farber Cancer Institute (Dana-Farber), to also produce NurOwn for the new Phase 2 progressive MS trial in addition to supporting ongoing production for the Phase 3 pivotal ALS trial.